Venture capitalist Oxford Capital has closed its Oxford Gateway Enterprise Investment Scheme (EIS) Fund No.4 to new investment, with total assets exceeding £12 million.

New investors still can access Oxford Capital’s tax-efficient EIS Funds structure and successful investment programme through the Oxford Gateway Fund No.5, launched on 6 May 2008.

Oxford Gateway Fund No.4, launched in November 2006, is currently being invested in a portfolio of high-growth businesses in the healthcare, sustainability and communications sectors. 

Investors in this fund will benefit from the significant tax advantages offered by the EIS Fund structure and its high-growth investment potential throughout the projected seven-year life of the fund.

Ted Mott, chief executive of Oxford Capital, says, ‘Our rolling programme of EIS Fund launches ensures that we always have a fund available for new investment. It also means that investors in our previous funds can reinvest capital returns as we realise investment gains in a highly tax-efficient manner. Investors in Oxford Gateway Fund No.1, launched in July 1999, have already seen a total net return of 2.8 times their original investment, with most of the gains coming in the first four years.

‘Oxford Gateway Fund No.4 is currently being invested in a portfolio of companies at the cutting edge of advances in the healthcare, sustainability and communications sectors.  These include one of the world’s leading nano-materials companies, Oxonica, whose enabling technology allows cleaner air in urban environments, Arieso, which provides network optimisation software for mobile telecoms operators to improve the quality of service while reducing the number of masts required, and Glide Pharma, a speciality pharmaceutical company enabling the fast and simple delivery of drugs and vaccines in solid formulation through the skin.’

For more information, visit www.oxcp.com